Educational Symposium
Accepting the Complement: Understanding the Role of Complement and Its Targeted Therapies in IgAN
October 24, 2024 | 12:45 PM - 01:45 PM
Location: TBD, Marriott Marquis
Session Description
Complement-mediated kidney disease extends from the ultra-rare, such as C3 glomerulopathy, to the most common in IgAN, and many in between. It has been nearly 15 years since eculizumab, the first complement targeting therapy, was approved for atypical hemolytic uremic syndrome. With complement targeting therapies on the horizon for glomerular diseases, nephrologists must understand the changing landscape of these therapies. This symposium addresses complement in IgAN. In particular, the pathogenesis of IgAN as a complement-mediated disease is discussed, as well as the role of complement targeted therapies in IgAN in a rapidly evolving therapeutic space.
Support is provided by an educational grant from Novartis Pharmaceuticals Corporation.
Learning Objective(s)
- Discuss the pathogenesis of IgAN as a complement-mediated disease
- Describe the recent advances in complement targeted therapy and its role in IgAN
Learning Pathway(s)
- Glomerular Diseases
Moderator
Presentations
- Introduction
12:45 PM - 12:55 PM
- Understanding IgAN as a Complement-Mediated Disease
12:55 PM - 01:15 PM
- Targeting Complement in IgAN
01:15 PM - 01:35 PM
- Audience Q&A
01:35 PM - 01:45 PM